

several novel somatic (e.g., tumor-specific) alterations, many of which have not previously been known to be genetically altered in tumors or linked to melanoma. In particular, the researchers identified a recurrent "hotspot" mutation in the transformation/transcription domain-associated protein (TRRAP) gene, identified the glutamate receptor ionotropic N-methyl D-aspartate 2A (GRIN2A) gene as a highly mutated in melanoma, and have shown that the majority of melanoma tumors have alternations in genes encoding members of the glutamate signaling pathway, such as phospholipase C, beta 4 (PLCB4). Therefore, this technology not only provides a comprehensive map of genetic alterations in melanoma, but has important diagnostic and therapeutic applications.

Available for licensing are several melanoma cell lines that harbor TRRAP, GRIN2A, and PLCB4 mutations. These cell lines provide useful and efficient tools for studying melanoma and can be used in the development of specific therapeutics for patients harboring these mutations. Specifically, these cell lines could be used to develop inhibitors to limit tumor growth and further understand melanoma and the biology of these genes.

Potential Commercial Applications:

- Diagnostic array for the detection of TRRAP, GRIN2A, and PLCB4 mutations.
- Method of identifying TRRAP, GRIN2A, and PLCB4 inhibitors as therapeutic agents to treat malignant melanoma patients.
- In vitro and in vivo cell model for understanding the biology of TRRAP, GRIN2A, and PLCB4, including growth, motility, invasion, and metabolite production.

Competitive Advantages:

- Cell lines are derived from melanoma patients.
- TRRAP, GRIN2A, and PLCB4 mutations are highly frequent and/or highly mutated in melanomas.
- Glutamate antagonists have already been shown to inhibit tumor growth. Thus, this technology may prove useful for the development of novel diagnostic tests and therapeutics.

Development Stage: Pre-clinical

Inventors: Yarden Samuels (NHGRI) and Steven Rosenberg (NCI)

Publication: Wei X, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat Genet.* 2011 May; 43(5):442–6. [PMID 21499247]

Intellectual Property: HHS Reference No. E-024-2012/0—Research Tool. Patent protection is not being pursued

for the TRRAP, GRIN2A, PLCB4 melanoma metastatic cell lines.

Related Technologies: HHS Reference Nos.—E-013-2011/0 (patent apps. PCT); E-272-2008/0 (patent apps. US, EP); E-229-2010/0 (research tool); E-232-2010/0 (research tool); E-029-2012/0 (research tool); E-244-2012/0 (patent app: PCT)

Licensing Contact: Whitney Hastings; 301-451-7337; hastingw@mail.nih.gov

Collaborative Research Opportunity: The NHGRI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Claire Driscoll, Director, NHGRI Technology Transfer Office, at cdriscoll@mail.nih.gov or 301-594-2235.

Dated: January 31, 2013.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013-02516 Filed 2-5-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Arthritis and Musculoskeletal and Skin Diseases Initial Review Group; Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Review Committee.

Date: March 12–13, 2013.

Time: 8:00 a.m. to 4:00 PM.

Agenda: To review and evaluate grant applications.

Place: Marriott Courtyard Gaithersburg Washingtonian Ctr, 204 Boardwalk Place, Gaithersburg, MD 20878.

Contact Person: Charles H Washabaugh, Ph.D., Scientific Review Officer, National

Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, 6701 Democracy Boulevard, Suite 800, Bethesda, MD 20892, (301) 496-9568, washabac@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: January 30, 2013.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-02517 Filed 2-5-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Clinical Trial Cobre.

Date: February 27, 2013.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott Courtyard Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Lisa A. Newman, SCD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3As.19K, Bethesda, MD 20892-4874, 301-594-2704, newmanla2@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: January 31, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-02515 Filed 2-5-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

Relocation of Regulations and Rulings, Office of International Trade

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: Notice of change in office location.

SUMMARY: Regulations and Rulings, in the Office of International Trade, of the U.S. Customs and Border Protection (CBP) is relocating its office from the U.S. Mint Annex Building at 799 9th Street NW., Washington, DC to 90 K Street NE., Washington, DC 20229-1177. All correspondence directed to the Regulations and Rulings, Office of International Trade, including mailed comments regarding section 1625 modifications or revocations, should be sent to the new address. The main office phone number remains the same.

DATES: *Effective Date:* February 6, 2013.

FOR FURTHER INFORMATION CONTACT: Joseph W. Clark, Trade and Commercial Regulations Branch, Regulations and Rulings, Office of International Trade, (202) 325-0118.

SUPPLEMENTARY INFORMATION:

Background

Regulations and Rulings, Office of International Trade, U.S. Customs and Border Protection (CBP) is relocating its office from the U.S. Mint Annex Building at 799 9th Street NW., Washington, DC to 90 K Street NE., Washington, DC 20229-1177. All correspondence, including ruling requests and mailed comments regarding 19 U.S.C. 1625 modifications or revocations (*see* 19 CFR 177.12), should be directed to the new address, as follows: Regulations and Rulings, Office of International Trade, U.S. Customs and Border Protection, 90 K St.

NE., (10th Floor), Washington, DC 20229-1177.

After February 4, 2013, anyone wishing to view the mailed comments that were submitted to Regulations and Rulings in response to a 1625 modification or revocation (19 CFR 177.12) published in the **Federal Register** should come to the new office location specified in the preceding paragraph. It is highly recommended that a person first call Mr. Joseph Clark at (202) 325-0118 to schedule an appointment in advance to view the comments. Please note that all office phone numbers remain the same. The main office phone number is 202-325-0100.

Dated: January 31, 2013.

Sandra L. Bell,

Executive Director, Regulations and Rulings, Office of International Trade.

[FR Doc. 2013-02546 Filed 2-5-13; 8:45 am]

BILLING CODE 9111-14-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-5683-N-12]

Notice of Submission of Proposed Information Collection to OMB HUD Lead Hazard Control Grantees Regarding Their Use of Healthy Homes Supplemental Funding

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

Requirements for notification of lead based paint hazard in federally-owned residential properties and housing receiving Federal assistance, as codified in 24 CFR part 35.

DATES: *Comments Due Date:* March 8, 2013.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval Number (2539-New) and

should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202-395-5806. Email: OIRA_Submission@omb.eop.gov fax: 202-395-5806.

FOR FURTHER INFORMATION CONTACT:

Colette Pollard., Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street SW., Washington, DC 20410; email Colette.Pollard@hud.gov. or telephone (202) 402-3400. This is not a toll-free number. Copies of available documents submitted to OMB may be obtained from Ms. Pollard.

SUPPLEMENTARY INFORMATION: This notice informs the public that the Department of Housing and Urban Development has submitted to OMB a request for approval of the Information collection described below. This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

This Notice Also Lists the Following Information

Title of Proposed: Collection of Information from HUD Lead Hazard Control Grantees Regarding Their Use of Healthy Homes Supplemental Funding.

OMB Approval Number: 2539-New.

Form Numbers: None.

Description of the need for the information and proposed use: Requirements for notification of leadbased paint hazard in federally-owned residential properties and housing receiving Federal assistance, as codified in 24 CFR part 35.

	Number of respondents	Annual responses	×	Hours per response	Burden hours
Reporting Burden	80	12		32.75	31,440